Dr Michael Makanga | Executive Director
European and Developing Countries Clinical Trials Partnership

Dr Michael Makanga, Executive Director, European and Developing Countries Clinical Trials Partnership

Dr Makanga is a clinician-scientist with 25 years of professional experience of working on health and poverty-related diseases in sub-Saharan Africa. This includes 21 years of work experience on medical product development and clinical regulatory activities. He holds a Medical Degree from Makerere University, Uganda, and has been in various clinical and research positions before and after undertaking a Master’s Degree at the University of Liverpool, and then a PhD at the Liverpool School of Tropical Medicine, United Kingdom. He is also a Fellow of the Royal College of Physicians of Edinburgh, Scotland.
 
Before joining EDCTP, Dr Makanga was first in clinical practice and academia, and later clinical research. He joined EDCTP in 2004 and has served in different progressive management positions prior to his current appointment. During the last 13 years at EDCTP, he has built up significant experience in global health, research for health capacity development, quality assurance, project management and evaluation, health and research management as well as diplomacy and engagement with policy makers, health and regulatory authorities in sub-Saharan Africa and Europe. Moreover, he has served in various scientific and policy advisory boards for international product development and philanthropic organisations along with pharmaceutical companies involved in developing medicinal products for poverty related and neglected diseases.

Appearances:



Day Two 11th October, Human @ 09:10

Plenary discussion: Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia

 
  • The role of emerging markets in the global supply and demand for vaccines
  • What vaccine technologies and vaccine candidates are favourable?
  • Does it align with other philanthropy organisations?
  • The role of Public-Public Partnerships (P2Ps) in vaccine R&D for poverty related and neglected diseases (PRNDs)
  • Priorities for linking new vaccine development with public health in low and middle income countries

back to speakers